- Home
- CEPU vs GLPG Comparison
CEPU vs GLPG Comparison
Compare CEPU & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- GLPG
- Stock Information
- Founded
- CEPU 1989
- GLPG 1999
- Country
- CEPU Argentina
- GLPG Belgium
- Employees
- CEPU N/A
- GLPG N/A
- Industry
- CEPU Electric Utilities: Central
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CEPU Utilities
- GLPG Health Care
- Exchange
- CEPU Nasdaq
- GLPG Nasdaq
- Market Cap
- CEPU 1.7B
- GLPG 2.0B
- IPO Year
- CEPU 2018
- GLPG 2005
- Fundamental
- Price
- CEPU $12.13
- GLPG $32.65
- Analyst Decision
- CEPU Hold
- GLPG Sell
- Analyst Count
- CEPU 1
- GLPG 4
- Target Price
- CEPU $12.00
- GLPG $25.33
- AVG Volume (30 Days)
- CEPU 215.5K
- GLPG 303.7K
- Earning Date
- CEPU 08-08-2025
- GLPG 07-23-2025
- Dividend Yield
- CEPU 2.56%
- GLPG N/A
- EPS Growth
- CEPU N/A
- GLPG N/A
- EPS
- CEPU 0.06
- GLPG N/A
- Revenue
- CEPU $697,204,690.00
- GLPG $323,721,668.00
- Revenue This Year
- CEPU $26.57
- GLPG $0.78
- Revenue Next Year
- CEPU N/A
- GLPG N/A
- P/E Ratio
- CEPU $20.38
- GLPG N/A
- Revenue Growth
- CEPU N/A
- GLPG 5.45
- 52 Week Low
- CEPU $7.07
- GLPG $22.36
- 52 Week High
- CEPU $16.60
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- CEPU 57.58
- GLPG 64.71
- Support Level
- CEPU $11.30
- GLPG $28.78
- Resistance Level
- CEPU $11.76
- GLPG $33.86
- Average True Range (ATR)
- CEPU 0.42
- GLPG 0.83
- MACD
- CEPU 0.11
- GLPG 0.20
- Stochastic Oscillator
- CEPU 89.29
- GLPG 78.58
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.